Phase I Clinical Trial of Allogeneic Bone Marrow Human Mesenchymal Stem Cells Loaded With A Tumor Selective Oncolytic Adenovirus, DNX-2401, Administered Via Intra-Arterial Injection in Patients With Recurrent High-Grade Glioma

This study is testing a new way to treat recurrent high-grade glioma, an aggressive type of brain tumor, using a modified common cold virus. The goal is to see if this virus, carried by stem cells, can specifically target and destroy cancer cells while keeping you safe.

This trial is for adults 18 or older who have a recurring brain tumor that has returned after previous treatments. You must meet specific health criteria, including having an MRI that shows the tumor is a certain size and having healthy enough blood vessels in your brain to receive the treatment safely.

You will receive the modified virus treatment through an artery that leads to the brain, and you may undergo surgery to help remove as much of the tumor as possible. Throughout the study, you will have regular clinic visits and tests so that doctors can monitor your health and see how your body responds to the treatment.

This study is currently recruiting patients in Houston, Texas. Because it is a phase I trial, the primary focus is on finding the right dose and understanding the safety of this new approach.